{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:22:03Z","timestamp":1790457723726,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ctrv.2021.102256","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:58:53Z","timestamp":1625637533000},"page":"102256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Repositioning PARP inhibitors in the treatment of thoracic malignancies"],"prefix":"10.1016","volume":"99","author":[{"given":"Francesco","family":"Passiglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia","family":"Reale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cetoretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parlagreco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"List\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-5076","authenticated-orcid":false,"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-9748","authenticated-orcid":false,"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7667","key":"10.1016\/j.ctrv.2021.102256_b0005","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2021.102256_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0015","doi-asserted-by":"crossref","first-page":"20223","DOI":"10.1038\/s41598-020-76975-6","article-title":"Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort","volume":"10","author":"Principe","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102256_b0020","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-20-2766","article-title":"PARP Inhibitors in Cancer Diagnosis and Therapy","volume":"27","author":"Chan","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102256_b0025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102256_b0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102256_b0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study","volume":"73","author":"Mateo","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102256_b0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102256_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2020.100068","article-title":"Somatic and germline BRCA 1 and 2 mutations in advanced NSCLC from the SAFIR02-lung trial","volume":"1","author":"Remon","year":"2020","journal-title":"JTO Clin Res Reports"},{"issue":"36","key":"10.1016\/j.ctrv.2021.102256_b0050","doi-asserted-by":"crossref","first-page":"57714","DOI":"10.18632\/oncotarget.9757","article-title":"ATM protein is deficient in over 40% of lung adenocarcinomas","volume":"7","author":"Villaruz","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102256_b0055","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","article-title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","volume":"121","author":"Jette","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1389450114666140106100909","article-title":"Therapeutic targeting of cancers with loss of PTEN function","volume":"15","author":"Dillon","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102256_b0065","doi-asserted-by":"crossref","first-page":"S562","DOI":"10.1016\/j.jtho.2019.08.1173","article-title":"P1.14-22 SASH1, a novel prognostic and predictive factor for PARP inhibitors in lung cancer","volume":"14","author":"Burgess","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102256_b0070","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.clgc.2015.12.029","article-title":"Expression levels of DNA damage repair proteins are associated with overall survival in platinum-treated advanced urothelial carcinoma","volume":"14","author":"Mullane","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"6330","key":"10.1016\/j.ctrv.2021.102256_b0075","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science (80-)"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102256_b0080","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/annonc\/mdu384","article-title":"A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer","volume":"25","author":"Novello","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102256_b0085","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1158\/1078-0432.CCR-15-3069","article-title":"Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced\/metastatic non-small cell lung cancer","volume":"23","author":"Ramalingam","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102256_b0090","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2017.04.010","article-title":"Smoking history predicts sensitivity to PARP inhibitor veliparib in patients with advanced non-small cell lung cancer","volume":"12","author":"Reck","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102256_b0095","unstructured":"AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer. Newsrelease 2017;North Chic(April):19."},{"key":"10.1016\/j.ctrv.2021.102256_b0100","doi-asserted-by":"crossref","unstructured":"Fennell DA, Lester JF, Danson S, et al. A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer. J Clin Oncol 2020;38(15_suppl):e21649. doi:10.1200\/JCO.2020.38.15_suppl.e21649.","DOI":"10.1200\/JCO.2020.38.15_suppl.e21649"},{"key":"10.1016\/j.ctrv.2021.102256_b0105","doi-asserted-by":"crossref","unstructured":"Postel-Vinay S, Planchard D, Antigny M, et al. Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: the phase 2 randomized PIPSeN trial. J Thor Oncol 2021 [International Association for the study of lung cancer]. doi:10.1016\/S.1556-0864(21)01942-0.","DOI":"10.1016\/S1556-0864(21)01942-0"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102256_b0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9022","article-title":"A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G)","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102256_b0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA damage and repair biomarkers of immunotherapy response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102256_b0120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: Infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102256_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12061502","article-title":"Combined parp inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0130","first-page":"1","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2021.102256_b0135","doi-asserted-by":"crossref","unstructured":"Bai X, Long L, Guo Z, et al. OA07.07 PARP1 inhibitors enhanced IFN\u03b3-induced PD-L1 expression in LKB1-mutant lung cancer. In: Abstracts | IASLC 2020 World Conference on Lung Cancer | Singapore, Worldwide Virtual Event; 2020:138\u20139. WCLC2020.IASLC.ORG.","DOI":"10.1016\/j.jtho.2021.01.298"},{"issue":"6230","key":"10.1016\/j.ctrv.2021.102256_b0140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102256_b0145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cllc.2018.09.008","article-title":"Association of tumor mutational burden with DNA repair mutations and response to Anti\u2013PD-1\/PD-L1 therapy in non\u2013small-cell lung cancer","volume":"20","author":"Chae","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102256_b0150","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","article-title":"Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer","volume":"26","author":"Ricciuti","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102256_b0155","doi-asserted-by":"crossref","unstructured":"Nie WBH. OA07.03 Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. In: Abstracts | IASLC 2020 World Conference on Lung Cancer | Singapore, Worldwide Virtual Event; 2020:134.","DOI":"10.1016\/j.jtho.2021.01.295"},{"key":"10.1016\/j.ctrv.2021.102256_b0160","doi-asserted-by":"crossref","unstructured":"Li Z, Niu Y, Ma THY, et al. MA13.03 DNA Damage Response Gene Alterations and their Association with Tumor Mutation Burden and Response to Immunotherapy in NSCLC and SCLC. In: Abstracts | IASLC 2020 World Conference on Lung Cancer | Singapore, Worldwide Virtual Event; 2020:282. WCLC2020.IASLC.ORG.","DOI":"10.1016\/j.jtho.2021.01.265"},{"key":"10.1016\/j.ctrv.2021.102256_b0165","unstructured":"Besse B, Awad M, Forde P, et al. OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, Who Progressed on Anti-PD(L)1 Therapy. In: Abstracts | IASLC 2020 World Conference on Lung Cancer | Singapore, Worldwide Virtual Event; 2020:140\u2013141. WCLC2020.IASLC.ORG."},{"issue":"47","key":"10.1016\/j.ctrv.2021.102256_b0170","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102256_b0175","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102256_b0180","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.celrep.2020.01.052","article-title":"Cooperation of the ATM and fanconi anemia\/BRCA pathways in double-strand break end resection","volume":"30","author":"Cai","year":"2020","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-66018-5","article-title":"Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer","volume":"10","author":"Ha","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102256_b0190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1541-7786.MCR-17-0455","article-title":"PARP1 trapping and DNA replication stress enhance radiosensitization with combined WEE1 and PARP inhibitors","volume":"16","author":"Parsels","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102256_b0195","doi-asserted-by":"crossref","unstructured":"Krebs MG, Lopez J, El-Khoueiry A, et al. Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. 2018;(D):CT026-CT026. doi:10.1158\/1538-7445.am2018-ct026.","DOI":"10.1158\/1538-7445.AM2018-CT026"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102256_b0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2021.102256_b0205","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/0008-5472.CAN-13-0044","article-title":"EGFR-activating mutations correlate with a fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity","volume":"73","author":"Pfa\u00e4ffle","year":"2013","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102256_b0210","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.celrep.2019.05.058","article-title":"Acquired resistance of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment promotes PARP inhibitor sensitivity","volume":"27","author":"Marcar","year":"2019","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102256_b0215","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","article-title":"Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations","volume":"17","author":"Rosell","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"October","key":"10.1016\/j.ctrv.2021.102256_b0220","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2020.09.018","article-title":"Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): a multicenter, randomized phase II study (GOAL)","volume":"150","author":"Garcia-Campelo","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102256_b0225","doi-asserted-by":"crossref","unstructured":"Karachaliou N, Arrieta O, Gimenez-Capitan A, et al. BRCA1 Expression and Outcomes in patients with EGFR-mutant NSCLC treated with gefitinib alone or in combination with Olaparib. JTO Clin Res Reports 2021;(March) doi:10.1016\/j.jtoccr.2020.100113.","DOI":"10.1016\/j.jtocrr.2020.100113"},{"issue":"40","key":"10.1016\/j.ctrv.2021.102256_b0230","doi-asserted-by":"crossref","first-page":"69105","DOI":"10.18632\/oncotarget.19079","article-title":"Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies","volume":"8","author":"Lesueur","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102256_b0235","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1158\/1078-0432.CCR-06-2872","article-title":"Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models","volume":"13","author":"Albert","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2021.102256_b0240","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 phase I multicenter study","volume":"36","author":"Jagsi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102256_b0245","article-title":"Phase 1 and pharmacological study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","author":"de Haan","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102256_b0250","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1200\/JCO.2016.34.15_suppl.8537","article-title":"SWOG S1206: A dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC)","volume":"34","author":"Cristea","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102256_b0255","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1200\/JCO.2019.37.15_suppl.8510","article-title":"Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin\/paclitaxel (C\/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14\u2013360\/AFT-07)","volume":"37","author":"Kozono","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0260","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-016-2275-x","article-title":"Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study","volume":"131","author":"Chabot","year":"2017","journal-title":"J Neurooncol"},{"issue":"7278","key":"10.1016\/j.ctrv.2021.102256_b0265","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature08629","article-title":"A small-cell lung cancer genome with complex signatures of tobacco exposure","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"issue":"7463","key":"10.1016\/j.ctrv.2021.102256_b0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"7563","key":"10.1016\/j.ctrv.2021.102256_b0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102256_b0280","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer","volume":"44","author":"Rudin","year":"2012","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102256_b0285","first-page":"798","volume":"2","author":"Yordy","year":"2013","journal-title":"NIH Public Access"},{"key":"10.1016\/j.ctrv.2021.102256_b0290","doi-asserted-by":"crossref","unstructured":"Sen T, Tong P, Wang J, Byers LA. Abstract LB-132: Proteomic profiling identifies ATM expression level as a predictive biomarker to ATR and PARP inhibition in small cell lung cancer (SCLC). Cancer Res 2016;76(14 suppl):LB-132 LP-LB-132. doi:10.1158\/1538-7445.AM2016-LB-132.","DOI":"10.1158\/1538-7445.AM2016-LB-132"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102256_b0295","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","article-title":"CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib","volume":"77","author":"Sen","year":"2017","journal-title":"Cancer Res"},{"issue":"578","key":"10.1016\/j.ctrv.2021.102256_b0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7488","article-title":"Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies","volume":"13","author":"Tlemsani","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102256_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0152584","article-title":"Activation of the PI3K\/mTOR pathway following PARP inhibition in small cell lung cancer","volume":"11","author":"Cardnell","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2021.102256_b0310","doi-asserted-by":"crossref","unstructured":"Byers LA, Wang J, Nilsson MB, et al. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discov 2012;2(9):798 LP - 811. doi:10.1158\/2159-8290.CD-12-0112.","DOI":"10.1158\/2159-8290.CD-12-0112"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102256_b0315","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/cam4.317","article-title":"Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer","volume":"3","author":"Owonikoko","year":"2014","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102256_b0320","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP Inhibitor activity correlates with slfn11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102256_b0325","doi-asserted-by":"crossref","unstructured":"Laird JH, Lok BH, Ma J, et al. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clin Cancer Res 2018;24(20):5143 LP - 5152. doi:10.1158\/1078-0432.CCR-18-0401.","DOI":"10.1158\/1078-0432.CCR-18-0401"},{"key":"10.1016\/j.ctrv.2021.102256_b0330","doi-asserted-by":"crossref","first-page":"S704","DOI":"10.1016\/j.jtho.2016.11.926","article-title":"P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC","volume":"12","author":"Woll","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102256_b0335","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102256_b0340","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker","volume":"18","author":"Pietanza","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102256_b0345","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J Clin Oncol"},{"issue":"S4","key":"10.1016\/j.ctrv.2021.102256_b0350","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.21037\/tlcr.2018.12.02","article-title":"Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"7","author":"Lazzari","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102256_b0355","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination olaparib and temozolomide in relapsed small-cell lung cancer","volume":"9","author":"Farago","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102256_b0360","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102256_b0365","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/1078-0432.CCR-18-2014","article-title":"A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors","volume":"25","author":"Atrafi","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102256_b0370","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102256_b0375","doi-asserted-by":"crossref","unstructured":"Sen T, Gay CM, Byers LA. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. 2018;7(1):50\u201368. doi:10.21037\/tlcr.2018.02.03.","DOI":"10.21037\/tlcr.2018.02.03"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102256_b0380","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.immuni.2015.01.012","article-title":"DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity","volume":"42","author":"H\u00e4rtlova","year":"2015","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102256_b0385","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102256_b0390","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102256_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102256_b0400","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2016.34.15_suppl.3015","article-title":"Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women\u2019s cancers (NCT02484404)","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102256_b0405","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study","volume":"14","author":"Thomas","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102256_b0410","doi-asserted-by":"crossref","first-page":"S2044","DOI":"10.1016\/j.jtho.2017.09.1040","article-title":"P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC","volume":"12","author":"Krebs","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102256_b0415","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-15840-5","article-title":"Targeting a non-oncogene addiction to the ATR\/CHK1 axis for the treatment of small cell lung cancer","volume":"7","author":"Doerr","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102256_b0425","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102256_b0430","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","article-title":"LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms","volume":"14","author":"King","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102256_b0435","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdy076","article-title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","volume":"29","author":"Italiano","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102256_b0440","doi-asserted-by":"crossref","unstructured":"Hamilton E, Falchook GS, Wang JS, et al. Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation. Cancer Res 2019;79(13 suppl):CT025\u2013CT025. doi:10.1158\/1538-7445.AM2019-CT025.","DOI":"10.1158\/1538-7445.AM2019-CT025"},{"key":"10.1016\/j.ctrv.2021.102256_b0445","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett"},{"issue":"28","key":"10.1016\/j.ctrv.2021.102256_b0450","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102256_b0455","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102256_b0460","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102256_b0465","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102256_b0470","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5314-0","article-title":"Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro","volume":"19","author":"Borchert","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102256_b0480","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102256_b0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082054","article-title":"Parp inhibitor resistance mechanisms and implications for post-progression combination therapies","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2021.102256_b0490","doi-asserted-by":"crossref","unstructured":"Fennell DA, Darlison L, Wells-Jordan P, et al. MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1\/BRCA1 deficient relapsed malignant mesothelioma. J Clin Oncol 2020;38(15_suppl):9057. doi:10.1200\/JCO.2020.38.15_suppl.9057.","DOI":"10.1200\/JCO.2020.38.15_suppl.9057"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102256_b0495","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.cllc.2020.07.014","article-title":"A prospective phase II single-arm study of Niraparib Plus Dostarlimab in patients with advanced non\u2013small-cell lung cancer and\/or malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: Rati","volume":"22","author":"Passiglia","year":"2020","journal-title":"Clin Lung Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:36Z","timestamp":1759656516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":99,"alternative-id":["S0305737221001043"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102256","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repositioning PARP inhibitors in the treatment of thoracic malignancies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102256"}}